Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Palliative Care | 183 | 2024 | 2037 | 30.330 |
Why?
|
Neoplasms | 227 | 2024 | 15204 | 14.460 |
Why?
|
Terminal Care | 39 | 2024 | 446 | 10.400 |
Why?
|
Delirium | 22 | 2024 | 207 | 8.660 |
Why?
|
Dyspnea | 31 | 2024 | 416 | 7.230 |
Why?
|
Sleep Apnea, Obstructive | 20 | 2022 | 229 | 6.760 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 29 | 2024 | 1026 | 5.960 |
Why?
|
Analgesics, Opioid | 46 | 2023 | 1372 | 5.490 |
Why?
|
Referral and Consultation | 35 | 2023 | 899 | 5.390 |
Why?
|
Continuous Positive Airway Pressure | 13 | 2022 | 80 | 5.360 |
Why?
|
Antipsychotic Agents | 12 | 2022 | 412 | 5.310 |
Why?
|
Influenza, Human | 29 | 2024 | 924 | 4.640 |
Why?
|
Coronavirus Infections | 23 | 2020 | 651 | 4.380 |
Why?
|
Medical Oncology | 26 | 2023 | 1425 | 4.220 |
Why?
|
Severe Acute Respiratory Syndrome | 25 | 2021 | 82 | 4.190 |
Why?
|
Symptom Assessment | 14 | 2023 | 271 | 4.020 |
Why?
|
Humans | 488 | 2024 | 262224 | 3.680 |
Why?
|
Cancer Care Facilities | 18 | 2023 | 884 | 3.490 |
Why?
|
Hospitalization | 44 | 2024 | 2118 | 3.370 |
Why?
|
Hong Kong | 51 | 2024 | 71 | 3.270 |
Why?
|
Respiratory Tract Infections | 12 | 2023 | 437 | 3.160 |
Why?
|
Fentanyl | 9 | 2022 | 148 | 3.100 |
Why?
|
Hospice and Palliative Care Nursing | 8 | 2023 | 56 | 3.100 |
Why?
|
Ambulatory Care | 17 | 2023 | 556 | 3.070 |
Why?
|
Opioid-Related Disorders | 15 | 2022 | 397 | 2.970 |
Why?
|
Quality of Life | 50 | 2023 | 4577 | 2.920 |
Why?
|
Quality of Health Care | 12 | 2020 | 626 | 2.870 |
Why?
|
Haloperidol | 10 | 2021 | 64 | 2.860 |
Why?
|
Pandemics | 29 | 2023 | 1566 | 2.640 |
Why?
|
Male | 273 | 2024 | 123279 | 2.570 |
Why?
|
Delivery of Health Care, Integrated | 7 | 2020 | 165 | 2.490 |
Why?
|
Severity of Illness Index | 37 | 2022 | 4348 | 2.440 |
Why?
|
Aged | 195 | 2024 | 70323 | 2.430 |
Why?
|
Middle Aged | 218 | 2024 | 86446 | 2.430 |
Why?
|
Prospective Studies | 80 | 2024 | 12914 | 2.420 |
Why?
|
Disease Outbreaks | 14 | 2022 | 416 | 2.340 |
Why?
|
Female | 261 | 2024 | 142251 | 2.300 |
Why?
|
Patient Care Team | 16 | 2020 | 799 | 2.300 |
Why?
|
Surveys and Questionnaires | 44 | 2024 | 5714 | 2.290 |
Why?
|
Influenza A Virus, H1N1 Subtype | 11 | 2023 | 242 | 2.250 |
Why?
|
Asthma | 10 | 2022 | 876 | 2.230 |
Why?
|
Respiratory Insufficiency | 6 | 2023 | 331 | 2.220 |
Why?
|
Adult | 177 | 2023 | 78088 | 2.180 |
Why?
|
Hospice Care | 10 | 2022 | 156 | 2.170 |
Why?
|
Pneumonia, Viral | 16 | 2020 | 715 | 2.140 |
Why?
|
Masks | 6 | 2020 | 57 | 2.110 |
Why?
|
Cancer Pain | 15 | 2023 | 312 | 2.080 |
Why?
|
Outpatients | 23 | 2023 | 461 | 2.080 |
Why?
|
Aged, 80 and over | 113 | 2024 | 29997 | 2.050 |
Why?
|
Exhalation | 8 | 2019 | 60 | 2.030 |
Why?
|
Pain | 25 | 2023 | 1675 | 1.990 |
Why?
|
Death | 7 | 2023 | 119 | 1.990 |
Why?
|
Polysomnography | 11 | 2021 | 155 | 1.940 |
Why?
|
Caregivers | 15 | 2021 | 680 | 1.940 |
Why?
|
Adrenal Cortex Hormones | 10 | 2024 | 548 | 1.930 |
Why?
|
Terminally Ill | 6 | 2021 | 91 | 1.920 |
Why?
|
Hospices | 4 | 2023 | 51 | 1.910 |
Why?
|
Patient Readmission | 8 | 2023 | 552 | 1.890 |
Why?
|
Middle East Respiratory Syndrome Coronavirus | 4 | 2018 | 28 | 1.880 |
Why?
|
Oxygen Inhalation Therapy | 8 | 2023 | 119 | 1.870 |
Why?
|
Prognosis | 51 | 2023 | 21747 | 1.790 |
Why?
|
Double-Blind Method | 20 | 2023 | 2598 | 1.780 |
Why?
|
Decision Making | 13 | 2023 | 1294 | 1.690 |
Why?
|
Exercise | 7 | 2021 | 1186 | 1.670 |
Why?
|
Patients | 7 | 2015 | 251 | 1.650 |
Why?
|
Dexamethasone | 7 | 2023 | 1450 | 1.650 |
Why?
|
Longitudinal Studies | 24 | 2021 | 1949 | 1.650 |
Why?
|
Cachexia | 10 | 2017 | 162 | 1.640 |
Why?
|
Pneumonia, Bacterial | 5 | 2015 | 130 | 1.610 |
Why?
|
Betacoronavirus | 12 | 2020 | 527 | 1.590 |
Why?
|
Benzodiazepines | 3 | 2022 | 170 | 1.560 |
Why?
|
Tertiary Care Centers | 8 | 2019 | 405 | 1.540 |
Why?
|
Physical Examination | 5 | 2015 | 299 | 1.530 |
Why?
|
Psychomotor Agitation | 3 | 2021 | 78 | 1.510 |
Why?
|
Hematologic Neoplasms | 6 | 2022 | 1870 | 1.480 |
Why?
|
Forced Expiratory Volume | 16 | 2019 | 314 | 1.480 |
Why?
|
Cannula | 3 | 2020 | 35 | 1.460 |
Why?
|
Spirituality | 9 | 2021 | 128 | 1.440 |
Why?
|
Specialization | 3 | 2015 | 132 | 1.440 |
Why?
|
Walking | 4 | 2019 | 277 | 1.420 |
Why?
|
Practice Patterns, Physicians' | 7 | 2018 | 1303 | 1.400 |
Why?
|
Critical Care | 11 | 2019 | 771 | 1.390 |
Why?
|
Coronavirus | 3 | 2014 | 40 | 1.380 |
Why?
|
Survival Analysis | 27 | 2023 | 9186 | 1.370 |
Why?
|
Electric Impedance | 4 | 2019 | 101 | 1.360 |
Why?
|
Fatigue | 17 | 2021 | 1239 | 1.350 |
Why?
|
Patient Compliance | 7 | 2015 | 669 | 1.330 |
Why?
|
Cross-Over Studies | 5 | 2020 | 462 | 1.310 |
Why?
|
Cross Infection | 6 | 2018 | 544 | 1.310 |
Why?
|
China | 16 | 2020 | 611 | 1.300 |
Why?
|
Antiemetics | 5 | 2021 | 125 | 1.270 |
Why?
|
Attitude of Health Personnel | 8 | 2021 | 928 | 1.270 |
Why?
|
Randomized Controlled Trials as Topic | 10 | 2023 | 2632 | 1.250 |
Why?
|
Palliative Medicine | 4 | 2021 | 23 | 1.250 |
Why?
|
Delivery of Health Care | 7 | 2024 | 868 | 1.240 |
Why?
|
Antiviral Agents | 18 | 2024 | 1232 | 1.200 |
Why?
|
National Cancer Institute (U.S.) | 4 | 2021 | 210 | 1.170 |
Why?
|
Minimal Clinically Important Difference | 2 | 2018 | 19 | 1.170 |
Why?
|
Communicable Diseases, Emerging | 6 | 2020 | 87 | 1.170 |
Why?
|
Respiratory Tract Diseases | 3 | 2022 | 111 | 1.160 |
Why?
|
Patient Preference | 6 | 2023 | 221 | 1.160 |
Why?
|
Air Pollution | 2 | 2022 | 89 | 1.150 |
Why?
|
Pain Management | 13 | 2021 | 670 | 1.130 |
Why?
|
Hand Strength | 3 | 2017 | 65 | 1.120 |
Why?
|
Young Adult | 53 | 2021 | 21474 | 1.110 |
Why?
|
Communication | 10 | 2023 | 882 | 1.110 |
Why?
|
Communicable Disease Control | 3 | 2023 | 175 | 1.110 |
Why?
|
Length of Stay | 11 | 2022 | 1930 | 1.100 |
Why?
|
Seasons | 8 | 2023 | 340 | 1.100 |
Why?
|
Models, Statistical | 4 | 2022 | 1177 | 1.090 |
Why?
|
Dementia | 2 | 2021 | 454 | 1.090 |
Why?
|
Air Pollutants | 2 | 2022 | 141 | 1.090 |
Why?
|
Lorazepam | 4 | 2021 | 40 | 1.080 |
Why?
|
Disease Progression | 14 | 2023 | 6695 | 1.080 |
Why?
|
Airway Obstruction | 2 | 2021 | 261 | 1.070 |
Why?
|
Lung | 10 | 2017 | 3157 | 1.070 |
Why?
|
Pilot Projects | 17 | 2023 | 2801 | 1.070 |
Why?
|
Respiratory Function Tests | 9 | 2023 | 319 | 1.070 |
Why?
|
Oncologists | 4 | 2023 | 134 | 1.060 |
Why?
|
Publishing | 3 | 2013 | 222 | 1.060 |
Why?
|
Anti-Inflammatory Agents | 4 | 2017 | 464 | 1.060 |
Why?
|
Systems Integration | 2 | 2015 | 76 | 1.050 |
Why?
|
Models, Organizational | 4 | 2020 | 75 | 1.040 |
Why?
|
Goals | 5 | 2023 | 188 | 1.030 |
Why?
|
Inpatients | 12 | 2023 | 688 | 1.030 |
Why?
|
Retrospective Studies | 70 | 2023 | 38010 | 1.020 |
Why?
|
Sleep Apnea Syndromes | 2 | 2021 | 82 | 1.010 |
Why?
|
Expert Testimony | 2 | 2015 | 90 | 1.000 |
Why?
|
Physicians | 6 | 2023 | 883 | 0.990 |
Why?
|
Bibliometrics | 3 | 2021 | 71 | 0.990 |
Why?
|
Models, Theoretical | 5 | 2015 | 786 | 0.980 |
Why?
|
Buprenorphine | 4 | 2018 | 96 | 0.980 |
Why?
|
Carotid Intima-Media Thickness | 2 | 2016 | 79 | 0.970 |
Why?
|
Drug Resistance, Bacterial | 4 | 2014 | 419 | 0.950 |
Why?
|
Cohort Studies | 28 | 2023 | 9293 | 0.940 |
Why?
|
Comorbidity | 18 | 2021 | 2394 | 0.940 |
Why?
|
Bacteria | 4 | 2021 | 608 | 0.930 |
Why?
|
Positive-Pressure Respiration | 5 | 2008 | 116 | 0.920 |
Why?
|
Terminology as Topic | 4 | 2014 | 416 | 0.910 |
Why?
|
Infectious Disease Transmission, Patient-to-Professional | 7 | 2020 | 58 | 0.910 |
Why?
|
Treatment Outcome | 44 | 2022 | 32991 | 0.880 |
Why?
|
Stress, Psychological | 10 | 2017 | 996 | 0.870 |
Why?
|
Point-of-Care Systems | 2 | 2023 | 195 | 0.870 |
Why?
|
Awareness | 2 | 2021 | 122 | 0.860 |
Why?
|
Practice Guidelines as Topic | 6 | 2021 | 2421 | 0.860 |
Why?
|
Body Composition | 5 | 2019 | 596 | 0.860 |
Why?
|
Respiration Disorders | 1 | 2022 | 45 | 0.850 |
Why?
|
Morphine | 12 | 2023 | 308 | 0.840 |
Why?
|
Spirometry | 9 | 2023 | 143 | 0.840 |
Why?
|
Pneumonia | 7 | 2022 | 754 | 0.830 |
Why?
|
Quality Indicators, Health Care | 2 | 2015 | 350 | 0.820 |
Why?
|
Professional-Family Relations | 2 | 2021 | 136 | 0.820 |
Why?
|
Exercise Tolerance | 3 | 2014 | 105 | 0.820 |
Why?
|
Physician-Patient Relations | 7 | 2023 | 802 | 0.820 |
Why?
|
Health Services Accessibility | 4 | 2017 | 764 | 0.810 |
Why?
|
Disclosure | 2 | 2021 | 181 | 0.810 |
Why?
|
Influenza A virus | 5 | 2023 | 270 | 0.800 |
Why?
|
Acute Disease | 8 | 2015 | 2424 | 0.790 |
Why?
|
Time Factors | 24 | 2021 | 12968 | 0.790 |
Why?
|
Nutritional Status | 3 | 2022 | 339 | 0.790 |
Why?
|
ROC Curve | 10 | 2019 | 1180 | 0.790 |
Why?
|
Forecasting | 3 | 2020 | 695 | 0.790 |
Why?
|
Intermittent Positive-Pressure Ventilation | 1 | 2021 | 13 | 0.790 |
Why?
|
Home Nursing | 2 | 2018 | 25 | 0.790 |
Why?
|
Health Impact Assessment | 1 | 2021 | 3 | 0.780 |
Why?
|
Heart Failure | 5 | 2023 | 2523 | 0.780 |
Why?
|
Anti-Bacterial Agents | 8 | 2023 | 2995 | 0.780 |
Why?
|
Religion and Medicine | 3 | 2018 | 50 | 0.770 |
Why?
|
Research Design | 7 | 2016 | 1562 | 0.770 |
Why?
|
Prevalence | 18 | 2019 | 3271 | 0.760 |
Why?
|
Adaptation, Psychological | 8 | 2024 | 763 | 0.750 |
Why?
|
Eosinophils | 2 | 2019 | 163 | 0.740 |
Why?
|
Monitoring, Physiologic | 2 | 2017 | 502 | 0.730 |
Why?
|
Quality Improvement | 3 | 2017 | 855 | 0.730 |
Why?
|
Edema | 2 | 2019 | 267 | 0.730 |
Why?
|
Acupuncture Points | 2 | 2010 | 18 | 0.730 |
Why?
|
Oxygen | 2 | 2023 | 754 | 0.720 |
Why?
|
Oseltamivir | 6 | 2024 | 33 | 0.720 |
Why?
|
Transcutaneous Electric Nerve Stimulation | 2 | 2010 | 26 | 0.710 |
Why?
|
Mental Competency | 1 | 2020 | 62 | 0.710 |
Why?
|
Bronchodilator Agents | 4 | 2024 | 220 | 0.710 |
Why?
|
Public Opinion | 1 | 2020 | 85 | 0.710 |
Why?
|
Home Care Services | 3 | 2017 | 92 | 0.710 |
Why?
|
Patient Dropouts | 3 | 2017 | 89 | 0.710 |
Why?
|
Family | 2 | 2021 | 737 | 0.700 |
Why?
|
Symptom Flare Up | 1 | 2019 | 29 | 0.700 |
Why?
|
Influenza A Virus, H3N2 Subtype | 6 | 2023 | 152 | 0.700 |
Why?
|
Rhinovirus | 1 | 2019 | 94 | 0.690 |
Why?
|
Benchmarking | 2 | 2021 | 272 | 0.690 |
Why?
|
Anti-Anxiety Agents | 2 | 2017 | 92 | 0.690 |
Why?
|
Lung Diseases, Interstitial | 1 | 2021 | 197 | 0.690 |
Why?
|
Metronidazole | 1 | 2020 | 151 | 0.680 |
Why?
|
Drug Therapy, Combination | 10 | 2024 | 2323 | 0.680 |
Why?
|
Atrial Natriuretic Factor | 1 | 2019 | 68 | 0.680 |
Why?
|
Nasopharynx | 6 | 2020 | 118 | 0.680 |
Why?
|
Health Status Indicators | 2 | 2019 | 227 | 0.680 |
Why?
|
Bacterial Infections | 4 | 2014 | 478 | 0.670 |
Why?
|
Sleep Stages | 2 | 2016 | 78 | 0.670 |
Why?
|
Sputum | 5 | 2020 | 141 | 0.670 |
Why?
|
Administration, Sublingual | 2 | 2019 | 25 | 0.670 |
Why?
|
Advance Care Planning | 1 | 2020 | 86 | 0.660 |
Why?
|
Weight Loss | 5 | 2022 | 629 | 0.660 |
Why?
|
Antibodies, Viral | 7 | 2023 | 1317 | 0.660 |
Why?
|
Risk Factors | 29 | 2022 | 17607 | 0.660 |
Why?
|
Depression | 12 | 2023 | 1715 | 0.660 |
Why?
|
Otolaryngology | 1 | 2020 | 128 | 0.650 |
Why?
|
Health Status | 3 | 2011 | 604 | 0.650 |
Why?
|
Water-Electrolyte Imbalance | 1 | 2019 | 92 | 0.640 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2023 | 1588 | 0.640 |
Why?
|
Tranquilizing Agents | 1 | 2018 | 6 | 0.640 |
Why?
|
Multivariate Analysis | 17 | 2019 | 4321 | 0.640 |
Why?
|
Asia | 4 | 2022 | 142 | 0.640 |
Why?
|
Cross-Sectional Studies | 17 | 2024 | 4330 | 0.640 |
Why?
|
Health Knowledge, Attitudes, Practice | 5 | 2021 | 1215 | 0.620 |
Why?
|
Vital Capacity | 4 | 2011 | 131 | 0.620 |
Why?
|
Uncertainty | 1 | 2019 | 321 | 0.610 |
Why?
|
Narcotics | 1 | 2018 | 123 | 0.610 |
Why?
|
Attitude to Death | 4 | 2020 | 100 | 0.610 |
Why?
|
Family Characteristics | 1 | 2018 | 102 | 0.610 |
Why?
|
Economics, Hospital | 1 | 2017 | 12 | 0.600 |
Why?
|
Opiate Substitution Treatment | 4 | 2018 | 30 | 0.600 |
Why?
|
Global Health | 5 | 2020 | 666 | 0.600 |
Why?
|
United States | 15 | 2023 | 15562 | 0.590 |
Why?
|
Electrodiagnosis | 1 | 2016 | 19 | 0.590 |
Why?
|
Adolescent | 36 | 2023 | 31258 | 0.590 |
Why?
|
Macrolides | 1 | 2017 | 62 | 0.590 |
Why?
|
Off-Label Use | 1 | 2017 | 46 | 0.590 |
Why?
|
Cytokines | 9 | 2021 | 2811 | 0.590 |
Why?
|
Nausea | 7 | 2021 | 525 | 0.580 |
Why?
|
Disease Transmission, Infectious | 1 | 2018 | 94 | 0.580 |
Why?
|
Azithromycin | 1 | 2017 | 78 | 0.580 |
Why?
|
Patient Acuity | 2 | 2020 | 74 | 0.570 |
Why?
|
Pectins | 1 | 2016 | 10 | 0.570 |
Why?
|
Reproducibility of Results | 11 | 2023 | 6036 | 0.570 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2019 | 341 | 0.560 |
Why?
|
Consensus | 7 | 2022 | 998 | 0.560 |
Why?
|
Conscious Sedation | 1 | 2017 | 104 | 0.560 |
Why?
|
Neuraminidase | 2 | 2022 | 69 | 0.560 |
Why?
|
Insulin Resistance | 1 | 2022 | 730 | 0.550 |
Why?
|
Intra-Abdominal Fat | 1 | 2016 | 95 | 0.550 |
Why?
|
Positive-Pressure Respiration, Intrinsic | 1 | 2015 | 3 | 0.550 |
Why?
|
Infection Control | 3 | 2022 | 270 | 0.550 |
Why?
|
Adiponectin | 1 | 2016 | 162 | 0.540 |
Why?
|
Hydrogen | 1 | 2015 | 57 | 0.540 |
Why?
|
Brazil | 6 | 2019 | 167 | 0.540 |
Why?
|
Undocumented Immigrants | 1 | 2015 | 17 | 0.540 |
Why?
|
Oxygen Consumption | 4 | 2011 | 398 | 0.540 |
Why?
|
Gastrointestinal Microbiome | 5 | 2022 | 905 | 0.540 |
Why?
|
Interdisciplinary Communication | 3 | 2018 | 280 | 0.540 |
Why?
|
Critical Pathways | 2 | 2018 | 150 | 0.530 |
Why?
|
Urban Health | 1 | 2015 | 76 | 0.530 |
Why?
|
Adenovirus Infections, Human | 1 | 2015 | 56 | 0.530 |
Why?
|
Virus Diseases | 3 | 2014 | 399 | 0.530 |
Why?
|
Non-alcoholic Fatty Liver Disease | 1 | 2021 | 421 | 0.520 |
Why?
|
Cross-Linking Reagents | 1 | 2015 | 153 | 0.520 |
Why?
|
Lysosomes | 3 | 2021 | 349 | 0.520 |
Why?
|
Republic of Korea | 7 | 2023 | 70 | 0.520 |
Why?
|
Superinfection | 1 | 2015 | 12 | 0.520 |
Why?
|
Paramyxoviridae Infections | 1 | 2015 | 86 | 0.510 |
Why?
|
Low Density Lipoprotein Receptor-Related Protein-1 | 3 | 2018 | 35 | 0.510 |
Why?
|
Primary Health Care | 3 | 2018 | 790 | 0.510 |
Why?
|
Patient Selection | 3 | 2019 | 2059 | 0.510 |
Why?
|
Thoracic Neoplasms | 1 | 2018 | 337 | 0.510 |
Why?
|
Internet | 1 | 2019 | 712 | 0.500 |
Why?
|
Bronchiectasis | 2 | 2014 | 26 | 0.500 |
Why?
|
Walk Test | 4 | 2019 | 43 | 0.500 |
Why?
|
Delphi Technique | 5 | 2022 | 214 | 0.500 |
Why?
|
Texas | 18 | 2017 | 6307 | 0.500 |
Why?
|
Psychometrics | 6 | 2023 | 947 | 0.500 |
Why?
|
Managed Care Programs | 1 | 2014 | 75 | 0.490 |
Why?
|
Age Factors | 14 | 2021 | 5386 | 0.490 |
Why?
|
C-Reactive Protein | 6 | 2022 | 526 | 0.490 |
Why?
|
Jordan | 4 | 2023 | 24 | 0.490 |
Why?
|
Respiratory Syncytial Virus Infections | 2 | 2015 | 427 | 0.490 |
Why?
|
Administration, Rectal | 1 | 2014 | 13 | 0.490 |
Why?
|
Breath Tests | 5 | 2012 | 175 | 0.490 |
Why?
|
Death, Sudden | 1 | 2014 | 59 | 0.490 |
Why?
|
Withholding Treatment | 2 | 2018 | 161 | 0.490 |
Why?
|
Inhalation | 1 | 2014 | 42 | 0.490 |
Why?
|
Medication Therapy Management | 1 | 2014 | 36 | 0.490 |
Why?
|
Vital Signs | 1 | 2014 | 25 | 0.490 |
Why?
|
Drug Resistance, Viral | 1 | 2014 | 71 | 0.480 |
Why?
|
Polymers | 1 | 2015 | 225 | 0.480 |
Why?
|
Drug Resistance, Fungal | 1 | 2014 | 92 | 0.480 |
Why?
|
Physical Exertion | 3 | 2020 | 113 | 0.470 |
Why?
|
Lactic Acid | 1 | 2015 | 306 | 0.470 |
Why?
|
Cough | 2 | 2012 | 117 | 0.470 |
Why?
|
Oncology Service, Hospital | 1 | 2013 | 48 | 0.470 |
Why?
|
Ambulatory Care Facilities | 4 | 2022 | 290 | 0.460 |
Why?
|
Spouse Abuse | 1 | 2013 | 22 | 0.460 |
Why?
|
Bronchitis, Chronic | 2 | 2011 | 30 | 0.450 |
Why?
|
Vomiting | 5 | 2021 | 354 | 0.450 |
Why?
|
Case Management | 1 | 2013 | 35 | 0.450 |
Why?
|
Guideline Adherence | 1 | 2017 | 638 | 0.450 |
Why?
|
Intensive Care Units | 8 | 2022 | 717 | 0.440 |
Why?
|
Viral Load | 5 | 2017 | 492 | 0.440 |
Why?
|
Mental Disorders | 2 | 2018 | 867 | 0.440 |
Why?
|
Genome, Viral | 1 | 2013 | 155 | 0.440 |
Why?
|
Obesity | 4 | 2022 | 2893 | 0.440 |
Why?
|
Hypnotics and Sedatives | 5 | 2022 | 220 | 0.430 |
Why?
|
Electroencephalography | 1 | 2017 | 897 | 0.430 |
Why?
|
Respiratory System | 2 | 2013 | 125 | 0.430 |
Why?
|
Mortality | 1 | 2014 | 346 | 0.430 |
Why?
|
Follow-Up Studies | 19 | 2022 | 14905 | 0.420 |
Why?
|
Comprehensive Health Care | 1 | 2012 | 49 | 0.420 |
Why?
|
Patient Education as Topic | 5 | 2019 | 757 | 0.420 |
Why?
|
Dust | 1 | 2012 | 39 | 0.410 |
Why?
|
Patient Care Planning | 5 | 2023 | 297 | 0.410 |
Why?
|
Life Style | 1 | 2015 | 615 | 0.410 |
Why?
|
Cannabis | 2 | 2023 | 67 | 0.410 |
Why?
|
Receptors, Cell Surface | 1 | 2015 | 862 | 0.410 |
Why?
|
Ventilation | 1 | 2011 | 20 | 0.410 |
Why?
|
Research Support as Topic | 1 | 2012 | 122 | 0.400 |
Why?
|
Protein Sorting Signals | 3 | 2002 | 44 | 0.400 |
Why?
|
Environment, Controlled | 1 | 2011 | 21 | 0.400 |
Why?
|
Carcinoma, Signet Ring Cell | 1 | 2013 | 170 | 0.400 |
Why?
|
Leukocytes, Mononuclear | 3 | 2021 | 704 | 0.400 |
Why?
|
Conflict of Interest | 1 | 2012 | 98 | 0.400 |
Why?
|
Bibliography of Medicine | 1 | 2011 | 3 | 0.400 |
Why?
|
Karnofsky Performance Status | 3 | 2016 | 175 | 0.400 |
Why?
|
Carotid Arteries | 2 | 2012 | 240 | 0.400 |
Why?
|
Patient Outcome Assessment | 1 | 2013 | 247 | 0.400 |
Why?
|
Hemolysin Proteins | 2 | 2002 | 27 | 0.390 |
Why?
|
Social Support | 1 | 2014 | 560 | 0.390 |
Why?
|
Antineoplastic Agents | 7 | 2021 | 14302 | 0.390 |
Why?
|
Mass Screening | 7 | 2022 | 1505 | 0.390 |
Why?
|
Rhinitis, Allergic, Perennial | 1 | 2010 | 9 | 0.380 |
Why?
|
Pulmonary Ventilation | 2 | 2010 | 45 | 0.380 |
Why?
|
Diagnostic Errors | 1 | 2015 | 510 | 0.380 |
Why?
|
Mycoses | 1 | 2014 | 386 | 0.380 |
Why?
|
Body Mass Index | 5 | 2020 | 2213 | 0.380 |
Why?
|
Biomarkers | 9 | 2023 | 5049 | 0.380 |
Why?
|
Rhinitis, Allergic, Seasonal | 1 | 2010 | 26 | 0.380 |
Why?
|
beta-Endorphin | 1 | 2010 | 42 | 0.370 |
Why?
|
Receptors, LDL | 1 | 2011 | 109 | 0.370 |
Why?
|
Lipoproteins, HDL | 1 | 2011 | 144 | 0.370 |
Why?
|
Diagnostic Equipment | 1 | 2010 | 1 | 0.370 |
Why?
|
Research | 1 | 2013 | 420 | 0.370 |
Why?
|
Interleukin-8 | 2 | 2010 | 520 | 0.360 |
Why?
|
Adrenergic beta-2 Receptor Agonists | 2 | 2024 | 106 | 0.360 |
Why?
|
Chlamydophila Infections | 1 | 2009 | 4 | 0.360 |
Why?
|
Chlamydophila pneumoniae | 1 | 2009 | 12 | 0.360 |
Why?
|
Sensitivity and Specificity | 10 | 2015 | 4977 | 0.360 |
Why?
|
Clinical Competence | 3 | 2019 | 1306 | 0.360 |
Why?
|
Mycoplasma pneumoniae | 1 | 2009 | 13 | 0.360 |
Why?
|
Deglutition Disorders | 1 | 2014 | 448 | 0.360 |
Why?
|
Incidence | 7 | 2019 | 5709 | 0.360 |
Why?
|
Community-Acquired Infections | 2 | 2009 | 285 | 0.360 |
Why?
|
Pneumonia, Mycoplasma | 1 | 2009 | 13 | 0.360 |
Why?
|
Encephalitis, Viral | 1 | 2010 | 30 | 0.350 |
Why?
|
Dose-Response Relationship, Drug | 6 | 2019 | 4943 | 0.350 |
Why?
|
Nitric Oxide | 2 | 2012 | 647 | 0.350 |
Why?
|
Pancreatic Neoplasms | 4 | 2015 | 5099 | 0.350 |
Why?
|
Leukotriene B4 | 1 | 2009 | 20 | 0.350 |
Why?
|
Precision Medicine | 3 | 2014 | 1158 | 0.340 |
Why?
|
Lung Volume Measurements | 1 | 2009 | 88 | 0.340 |
Why?
|
Dysbiosis | 2 | 2021 | 134 | 0.340 |
Why?
|
Neoplasm Staging | 7 | 2019 | 13672 | 0.340 |
Why?
|
Evolution, Molecular | 1 | 2013 | 834 | 0.340 |
Why?
|
Influenza A Virus, H5N1 Subtype | 3 | 2017 | 68 | 0.340 |
Why?
|
Patient Discharge | 4 | 2013 | 667 | 0.340 |
Why?
|
Age Distribution | 4 | 2015 | 704 | 0.340 |
Why?
|
Drug Resistance, Microbial | 2 | 2023 | 217 | 0.340 |
Why?
|
Singapore | 4 | 2020 | 31 | 0.340 |
Why?
|
Hepatocytes | 1 | 2011 | 347 | 0.330 |
Why?
|
Statistics, Nonparametric | 7 | 2017 | 980 | 0.330 |
Why?
|
Cell Membrane | 2 | 2018 | 855 | 0.330 |
Why?
|
Molecular Diagnostic Techniques | 3 | 2019 | 333 | 0.330 |
Why?
|
Enzyme Inhibitors | 2 | 2022 | 1879 | 0.330 |
Why?
|
Chemokines, CXC | 2 | 2005 | 117 | 0.330 |
Why?
|
Substance Abuse Detection | 2 | 2020 | 64 | 0.320 |
Why?
|
Camelus | 3 | 2018 | 7 | 0.320 |
Why?
|
Survivors | 3 | 2017 | 1035 | 0.320 |
Why?
|
Quality Assurance, Health Care | 1 | 2013 | 590 | 0.320 |
Why?
|
Influenza A Virus, H7N9 Subtype | 3 | 2017 | 25 | 0.310 |
Why?
|
Aerosols | 4 | 2020 | 158 | 0.310 |
Why?
|
Liver | 4 | 2020 | 2906 | 0.310 |
Why?
|
Anorexia | 3 | 2021 | 143 | 0.310 |
Why?
|
Physical Fitness | 2 | 2005 | 125 | 0.310 |
Why?
|
Meta-Analysis as Topic | 1 | 2009 | 279 | 0.310 |
Why?
|
Pain Measurement | 7 | 2021 | 983 | 0.310 |
Why?
|
Vaccines | 2 | 2024 | 391 | 0.310 |
Why?
|
RNA Viruses | 1 | 2007 | 43 | 0.300 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2010 | 604 | 0.300 |
Why?
|
Sleep Initiation and Maintenance Disorders | 2 | 2023 | 134 | 0.300 |
Why?
|
Noninvasive Ventilation | 2 | 2020 | 37 | 0.300 |
Why?
|
Coronary Artery Disease | 1 | 2015 | 1017 | 0.300 |
Why?
|
Self Report | 4 | 2024 | 766 | 0.300 |
Why?
|
Motor Vehicles | 1 | 2006 | 9 | 0.290 |
Why?
|
Analgesics | 1 | 2010 | 394 | 0.290 |
Why?
|
Patient Simulation | 3 | 2012 | 42 | 0.290 |
Why?
|
Antibodies, Neoplasm | 1 | 2008 | 258 | 0.290 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2010 | 1539 | 0.290 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2015 | 847 | 0.290 |
Why?
|
Cost of Illness | 4 | 2017 | 502 | 0.290 |
Why?
|
Substance-Related Disorders | 3 | 2024 | 529 | 0.290 |
Why?
|
Exercise Therapy | 2 | 2012 | 291 | 0.290 |
Why?
|
Automobile Driving | 1 | 2006 | 30 | 0.290 |
Why?
|
Poultry | 2 | 2017 | 10 | 0.290 |
Why?
|
Adenocarcinoma | 2 | 2015 | 7793 | 0.290 |
Why?
|
Inflammation Mediators | 1 | 2009 | 421 | 0.290 |
Why?
|
Periodicals as Topic | 1 | 2011 | 338 | 0.280 |
Why?
|
Resuscitation Orders | 3 | 2013 | 68 | 0.280 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 3 | 2021 | 5339 | 0.280 |
Why?
|
Serum Albumin | 3 | 2017 | 252 | 0.280 |
Why?
|
Patient Reported Outcome Measures | 2 | 2023 | 803 | 0.280 |
Why?
|
Influenza in Birds | 2 | 2017 | 26 | 0.280 |
Why?
|
Prostaglandins A | 1 | 2005 | 2 | 0.270 |
Why?
|
Case-Control Studies | 10 | 2016 | 6105 | 0.270 |
Why?
|
Hospital Mortality | 3 | 2022 | 1309 | 0.270 |
Why?
|
Chiroptera | 2 | 2016 | 45 | 0.260 |
Why?
|
Apolipoproteins E | 2 | 2008 | 220 | 0.260 |
Why?
|
ATP Binding Cassette Transporter 1 | 2 | 2018 | 29 | 0.260 |
Why?
|
Anxiety | 6 | 2023 | 1189 | 0.260 |
Why?
|
Patient Satisfaction | 6 | 2017 | 928 | 0.260 |
Why?
|
Ritonavir | 2 | 2023 | 67 | 0.260 |
Why?
|
Logistic Models | 8 | 2014 | 3450 | 0.260 |
Why?
|
Phosphodiesterase 4 Inhibitors | 2 | 2017 | 24 | 0.260 |
Why?
|
Sex Distribution | 3 | 2015 | 497 | 0.260 |
Why?
|
Leukocyte Count | 2 | 2019 | 684 | 0.250 |
Why?
|
CDC2 Protein Kinase | 1 | 2005 | 177 | 0.250 |
Why?
|
South America | 2 | 2022 | 52 | 0.250 |
Why?
|
Clinical Trials as Topic | 2 | 2012 | 3752 | 0.250 |
Why?
|
Nomograms | 2 | 2021 | 314 | 0.250 |
Why?
|
Chemokine CCL2 | 1 | 2005 | 195 | 0.250 |
Why?
|
Metagenomics | 2 | 2022 | 115 | 0.250 |
Why?
|
Exercise Test | 3 | 2013 | 306 | 0.250 |
Why?
|
Escherichia coli | 2 | 2002 | 1214 | 0.250 |
Why?
|
Appetite | 2 | 2016 | 73 | 0.250 |
Why?
|
Tuberculosis Vaccines | 1 | 2024 | 13 | 0.240 |
Why?
|
Survival Rate | 6 | 2019 | 12236 | 0.240 |
Why?
|
Hiccup | 2 | 2015 | 17 | 0.240 |
Why?
|
Guanidines | 2 | 2015 | 60 | 0.240 |
Why?
|
Models, Biological | 3 | 2010 | 3250 | 0.240 |
Why?
|
Cyclopentanes | 2 | 2015 | 41 | 0.230 |
Why?
|
Existentialism | 2 | 2021 | 9 | 0.230 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 2 | 2014 | 1666 | 0.230 |
Why?
|
Platelet Activation | 1 | 2004 | 116 | 0.230 |
Why?
|
Body Dysmorphic Disorders | 2 | 2014 | 31 | 0.230 |
Why?
|
Aspartate Aminotransferases | 2 | 2021 | 153 | 0.230 |
Why?
|
Administration, Intranasal | 2 | 2016 | 193 | 0.230 |
Why?
|
Cardiovascular Diseases | 2 | 2019 | 2205 | 0.230 |
Why?
|
Antioxidants | 2 | 2013 | 514 | 0.230 |
Why?
|
Advance Directives | 2 | 2015 | 88 | 0.230 |
Why?
|
Child, Preschool | 13 | 2021 | 16256 | 0.230 |
Why?
|
Proportional Hazards Models | 6 | 2018 | 5008 | 0.230 |
Why?
|
Psychological Tests | 1 | 2024 | 131 | 0.220 |
Why?
|
Vena Cava, Superior | 1 | 2023 | 78 | 0.220 |
Why?
|
Lymphoma, Mantle-Cell | 2 | 2006 | 717 | 0.220 |
Why?
|
Health Personnel | 4 | 2020 | 631 | 0.220 |
Why?
|
Alanine Transaminase | 2 | 2021 | 227 | 0.220 |
Why?
|
Clinical Laboratory Techniques | 2 | 2020 | 203 | 0.220 |
Why?
|
Fluid Therapy | 2 | 2015 | 181 | 0.220 |
Why?
|
Predictive Value of Tests | 8 | 2014 | 4902 | 0.220 |
Why?
|
Computers | 1 | 2023 | 141 | 0.220 |
Why?
|
Hydrazines | 2 | 2021 | 208 | 0.220 |
Why?
|
Attitude to Health | 3 | 2017 | 466 | 0.220 |
Why?
|
Tumor Suppressor Proteins | 1 | 2011 | 1829 | 0.220 |
Why?
|
Cannabinoids | 1 | 2023 | 39 | 0.220 |
Why?
|
Patient Admission | 3 | 2014 | 222 | 0.220 |
Why?
|
Animals | 17 | 2021 | 59540 | 0.220 |
Why?
|
Outpatient Clinics, Hospital | 2 | 2013 | 97 | 0.220 |
Why?
|
Nursing Assessment | 2 | 2013 | 42 | 0.220 |
Why?
|
Cerebral Infarction | 1 | 2002 | 60 | 0.210 |
Why?
|
Molecular Targeted Therapy | 1 | 2013 | 2332 | 0.210 |
Why?
|
Religion | 2 | 2014 | 90 | 0.210 |
Why?
|
Fatal Outcome | 2 | 2015 | 828 | 0.210 |
Why?
|
Dibenzothiepins | 1 | 2022 | 6 | 0.210 |
Why?
|
Tuberculosis, Multidrug-Resistant | 1 | 2024 | 124 | 0.210 |
Why?
|
International Cooperation | 2 | 2021 | 323 | 0.210 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2005 | 647 | 0.210 |
Why?
|
Survival | 2 | 2014 | 177 | 0.210 |
Why?
|
Air Microbiology | 2 | 2012 | 30 | 0.210 |
Why?
|
Drug Combinations | 2 | 2021 | 622 | 0.210 |
Why?
|
Muscarinic Antagonists | 2 | 2024 | 84 | 0.200 |
Why?
|
ATP-Binding Cassette Transporters | 4 | 2011 | 300 | 0.200 |
Why?
|
Sickness Impact Profile | 2 | 2013 | 141 | 0.200 |
Why?
|
Australasia | 1 | 2021 | 5 | 0.200 |
Why?
|
Adaptive Immunity | 1 | 2022 | 150 | 0.200 |
Why?
|
Administration, Inhalation | 2 | 2024 | 286 | 0.200 |
Why?
|
Urine | 3 | 2020 | 143 | 0.200 |
Why?
|
Immunoglobulin G | 1 | 2005 | 1027 | 0.200 |
Why?
|
Neuralgia, Postherpetic | 1 | 2021 | 8 | 0.200 |
Why?
|
Civil Defense | 1 | 2021 | 13 | 0.200 |
Why?
|
Feces | 3 | 2022 | 772 | 0.200 |
Why?
|
Herpes Zoster Vaccine | 1 | 2021 | 11 | 0.200 |
Why?
|
Oxymorphone | 1 | 2021 | 9 | 0.200 |
Why?
|
Pressure Ulcer | 1 | 2022 | 106 | 0.200 |
Why?
|
Integrative Oncology | 1 | 2021 | 30 | 0.190 |
Why?
|
Tobacco Use | 2 | 2018 | 55 | 0.190 |
Why?
|
Epidemics | 2 | 2019 | 63 | 0.190 |
Why?
|
Gastrointestinal Tract | 2 | 2021 | 327 | 0.190 |
Why?
|
Lung Neoplasms | 3 | 2021 | 11573 | 0.190 |
Why?
|
Government Regulation | 1 | 2021 | 67 | 0.190 |
Why?
|
Zoonoses | 2 | 2018 | 55 | 0.190 |
Why?
|
Quinuclidines | 1 | 2021 | 48 | 0.190 |
Why?
|
Herpes Zoster | 1 | 2021 | 51 | 0.190 |
Why?
|
Water | 1 | 2022 | 364 | 0.190 |
Why?
|
Testosterone | 4 | 2014 | 620 | 0.190 |
Why?
|
Isoquinolines | 1 | 2021 | 116 | 0.190 |
Why?
|
Midazolam | 2 | 2018 | 75 | 0.190 |
Why?
|
Real-Time Polymerase Chain Reaction | 4 | 2021 | 1223 | 0.180 |
Why?
|
Data Accuracy | 1 | 2020 | 54 | 0.180 |
Why?
|
Acute Lung Injury | 1 | 2021 | 92 | 0.180 |
Why?
|
Stomach Neoplasms | 1 | 2013 | 2282 | 0.180 |
Why?
|
Antibodies, Neutralizing | 2 | 2023 | 547 | 0.180 |
Why?
|
Adenosine Monophosphate | 1 | 2020 | 76 | 0.180 |
Why?
|
Hydromorphone | 4 | 2023 | 58 | 0.180 |
Why?
|
Glucocorticoids | 4 | 2010 | 637 | 0.180 |
Why?
|
RNA, Viral | 5 | 2020 | 667 | 0.180 |
Why?
|
Oral Sprays | 1 | 2019 | 8 | 0.180 |
Why?
|
Hepatitis B, Chronic | 1 | 2021 | 137 | 0.180 |
Why?
|
Mycobacterium tuberculosis | 1 | 2024 | 430 | 0.180 |
Why?
|
Alanine | 1 | 2020 | 239 | 0.170 |
Why?
|
Antibodies, Monoclonal | 2 | 2014 | 4382 | 0.170 |
Why?
|
Lymph Nodes | 1 | 2010 | 2969 | 0.170 |
Why?
|
Saliva | 1 | 2020 | 230 | 0.170 |
Why?
|
Water-Electrolyte Balance | 1 | 2019 | 104 | 0.170 |
Why?
|
Propensity Score | 1 | 2022 | 755 | 0.170 |
Why?
|
Escherichia coli Proteins | 1 | 2002 | 361 | 0.170 |
Why?
|
Feasibility Studies | 2 | 2016 | 2300 | 0.170 |
Why?
|
Influenza Vaccines | 2 | 2023 | 635 | 0.170 |
Why?
|
Alcohol Withdrawal Delirium | 1 | 2018 | 1 | 0.170 |
Why?
|
Air Movements | 2 | 2010 | 7 | 0.170 |
Why?
|
Oxidative Stress | 1 | 2005 | 1132 | 0.170 |
Why?
|
Metabolome | 1 | 2022 | 343 | 0.170 |
Why?
|
Ribavirin | 3 | 2020 | 178 | 0.170 |
Why?
|
Intestinal Obstruction | 1 | 2021 | 202 | 0.170 |
Why?
|
Risk Assessment | 7 | 2021 | 6891 | 0.170 |
Why?
|
Hypogonadism | 2 | 2014 | 257 | 0.170 |
Why?
|
Unnecessary Procedures | 1 | 2019 | 104 | 0.170 |
Why?
|
Nutritional Support | 2 | 2017 | 80 | 0.170 |
Why?
|
Hypoalphalipoproteinemias | 1 | 2018 | 2 | 0.160 |
Why?
|
Substance Abuse Treatment Centers | 1 | 2018 | 13 | 0.160 |
Why?
|
Scavenger Receptors, Class B | 1 | 2018 | 9 | 0.160 |
Why?
|
Immunity | 1 | 2021 | 343 | 0.160 |
Why?
|
Saudi Arabia | 1 | 2018 | 39 | 0.160 |
Why?
|
Interferons | 2 | 2024 | 290 | 0.160 |
Why?
|
Diabetes Complications | 1 | 2020 | 310 | 0.160 |
Why?
|
Tuberculosis, Pulmonary | 2 | 2014 | 247 | 0.160 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2020 | 566 | 0.160 |
Why?
|
Acids, Carbocyclic | 2 | 2015 | 3 | 0.160 |
Why?
|
Heart Rate | 2 | 2015 | 736 | 0.160 |
Why?
|
Manikins | 1 | 2019 | 137 | 0.160 |
Why?
|
Microtubule-Associated Proteins | 1 | 2021 | 534 | 0.160 |
Why?
|
Deep Sedation | 1 | 2018 | 21 | 0.160 |
Why?
|
Patient Participation | 2 | 2023 | 462 | 0.160 |
Why?
|
Administration, Buccal | 1 | 2017 | 5 | 0.160 |
Why?
|
Vaccination | 2 | 2022 | 1124 | 0.160 |
Why?
|
Middle East | 2 | 2015 | 47 | 0.150 |
Why?
|
Air Pollution, Indoor | 2 | 2009 | 39 | 0.150 |
Why?
|
Area Under Curve | 1 | 2019 | 701 | 0.150 |
Why?
|
CD55 Antigens | 1 | 2017 | 17 | 0.150 |
Why?
|
Toll-Like Receptor 3 | 1 | 2017 | 23 | 0.150 |
Why?
|
Interprofessional Relations | 1 | 2019 | 215 | 0.150 |
Why?
|
Immunotherapy | 3 | 2022 | 3345 | 0.150 |
Why?
|
Meteorological Concepts | 2 | 2019 | 4 | 0.150 |
Why?
|
Kaplan-Meier Estimate | 10 | 2022 | 6219 | 0.150 |
Why?
|
Chemokines | 2 | 2011 | 314 | 0.150 |
Why?
|
Narcotic Antagonists | 1 | 2018 | 129 | 0.150 |
Why?
|
Tuberculosis | 1 | 2024 | 555 | 0.150 |
Why?
|
Cooperative Behavior | 2 | 2018 | 314 | 0.150 |
Why?
|
Virus Shedding | 3 | 2020 | 88 | 0.150 |
Why?
|
Triazoles | 1 | 2021 | 620 | 0.150 |
Why?
|
Microbiota | 1 | 2023 | 543 | 0.150 |
Why?
|
Consciousness | 1 | 2017 | 56 | 0.150 |
Why?
|
Hypodermoclysis | 1 | 2016 | 4 | 0.150 |
Why?
|
Health Services Needs and Demand | 1 | 2019 | 245 | 0.150 |
Why?
|
Risperidone | 1 | 2017 | 62 | 0.140 |
Why?
|
Nasal Sprays | 1 | 2016 | 7 | 0.140 |
Why?
|
Cholesterol, HDL | 1 | 2018 | 342 | 0.140 |
Why?
|
Infant | 7 | 2021 | 13299 | 0.140 |
Why?
|
Health Plan Implementation | 1 | 2017 | 91 | 0.140 |
Why?
|
Politics | 2 | 2020 | 75 | 0.140 |
Why?
|
Propofol | 1 | 2017 | 80 | 0.140 |
Why?
|
Informed Consent | 1 | 2020 | 419 | 0.140 |
Why?
|
Sex Factors | 3 | 2016 | 2156 | 0.140 |
Why?
|
Physical Stimulation | 2 | 2006 | 112 | 0.140 |
Why?
|
Aging | 3 | 2018 | 1538 | 0.140 |
Why?
|
Prednisolone | 3 | 2005 | 123 | 0.140 |
Why?
|
Socioeconomic Factors | 4 | 2015 | 1230 | 0.140 |
Why?
|
Food Packaging | 1 | 2015 | 1 | 0.140 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2021 | 1035 | 0.140 |
Why?
|
Steam | 1 | 2015 | 6 | 0.140 |
Why?
|
Plasma | 1 | 2017 | 159 | 0.140 |
Why?
|
Physician's Role | 1 | 2018 | 241 | 0.140 |
Why?
|
Chemical Phenomena | 1 | 2015 | 137 | 0.140 |
Why?
|
Drug Discovery | 2 | 2020 | 328 | 0.140 |
Why?
|
Bacterial Proteins | 1 | 2002 | 1032 | 0.140 |
Why?
|
Time-to-Treatment | 1 | 2018 | 293 | 0.140 |
Why?
|
Hydroxyeicosatetraenoic Acids | 1 | 2015 | 36 | 0.140 |
Why?
|
Polyesters | 1 | 2015 | 54 | 0.140 |
Why?
|
Hydrocortisone | 3 | 2014 | 389 | 0.130 |
Why?
|
Interleukin-1 Receptor-Like 1 Protein | 1 | 2015 | 30 | 0.130 |
Why?
|
Bereavement | 1 | 2015 | 27 | 0.130 |
Why?
|
Health Behavior | 1 | 2020 | 602 | 0.130 |
Why?
|
Drugs, Chinese Herbal | 1 | 2016 | 58 | 0.130 |
Why?
|
Receptors, Interleukin-1 | 1 | 2015 | 94 | 0.130 |
Why?
|
Hydrophobic and Hydrophilic Interactions | 1 | 2015 | 88 | 0.130 |
Why?
|
Influenza A Virus, H10N8 Subtype | 1 | 2015 | 1 | 0.130 |
Why?
|
Organizational Innovation | 1 | 2015 | 70 | 0.130 |
Why?
|
Child | 14 | 2021 | 29137 | 0.130 |
Why?
|
Surface Properties | 1 | 2015 | 181 | 0.130 |
Why?
|
Surgical Procedures, Operative | 1 | 2019 | 383 | 0.130 |
Why?
|
Urban Population | 1 | 2016 | 269 | 0.130 |
Why?
|
Immunity, Innate | 2 | 2024 | 678 | 0.130 |
Why?
|
RNA-Binding Proteins | 2 | 2021 | 984 | 0.130 |
Why?
|
Autonomic Nervous System | 1 | 2015 | 72 | 0.130 |
Why?
|
Fatty Acids, Unsaturated | 1 | 2015 | 94 | 0.130 |
Why?
|
Beijing | 1 | 2015 | 13 | 0.130 |
Why?
|
Odds Ratio | 3 | 2022 | 2326 | 0.130 |
Why?
|
Zanamivir | 1 | 2015 | 8 | 0.130 |
Why?
|
Video Recording | 2 | 2007 | 266 | 0.130 |
Why?
|
Arachidonate 15-Lipoxygenase | 1 | 2015 | 90 | 0.130 |
Why?
|
Regression Analysis | 2 | 2015 | 1550 | 0.130 |
Why?
|
Probability | 3 | 2014 | 868 | 0.130 |
Why?
|
Polymerase Chain Reaction | 3 | 2011 | 3190 | 0.130 |
Why?
|
Carbon | 1 | 2015 | 150 | 0.130 |
Why?
|
Canada | 2 | 2021 | 431 | 0.130 |
Why?
|
Physical Endurance | 2 | 2005 | 58 | 0.130 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 4 | 2021 | 3637 | 0.130 |
Why?
|
Amino Acid Sequence | 6 | 2005 | 4235 | 0.130 |
Why?
|
Hot Temperature | 1 | 2015 | 280 | 0.130 |
Why?
|
Vocal Cords | 1 | 2015 | 90 | 0.120 |
Why?
|
Radiography, Thoracic | 4 | 2004 | 460 | 0.120 |
Why?
|
Medicine | 1 | 2016 | 136 | 0.120 |
Why?
|
Protective Factors | 1 | 2015 | 107 | 0.120 |
Why?
|
Infectious Disease Incubation Period | 1 | 2014 | 8 | 0.120 |
Why?
|
Refuse Disposal | 1 | 2014 | 10 | 0.120 |
Why?
|
Adjuvants, Anesthesia | 1 | 2014 | 8 | 0.120 |
Why?
|
Family Relations | 1 | 2015 | 88 | 0.120 |
Why?
|
Linear Models | 2 | 2014 | 1090 | 0.120 |
Why?
|
Influenza B virus | 2 | 2012 | 127 | 0.120 |
Why?
|
Atropine | 1 | 2014 | 52 | 0.120 |
Why?
|
Mouth | 1 | 2015 | 122 | 0.120 |
Why?
|
Erythrocytes | 1 | 2015 | 339 | 0.120 |
Why?
|
Drug Storage | 1 | 2014 | 29 | 0.120 |
Why?
|
Frail Elderly | 1 | 2015 | 118 | 0.120 |
Why?
|
Statistics as Topic | 1 | 2015 | 444 | 0.120 |
Why?
|
Eyelids | 1 | 2015 | 163 | 0.120 |
Why?
|
Biological Therapy | 1 | 2014 | 58 | 0.120 |
Why?
|
Disease Management | 1 | 2020 | 1060 | 0.120 |
Why?
|
Smoking | 2 | 2015 | 2444 | 0.120 |
Why?
|
Communication Barriers | 1 | 2014 | 52 | 0.120 |
Why?
|
Interleukin-1alpha | 1 | 2014 | 55 | 0.120 |
Why?
|
Demography | 1 | 2015 | 437 | 0.120 |
Why?
|
Diet, High-Fat | 1 | 2015 | 241 | 0.120 |
Why?
|
Subcutaneous Absorption | 1 | 2013 | 4 | 0.120 |
Why?
|
Pyridines | 1 | 2021 | 1245 | 0.120 |
Why?
|
Molecular Sequence Data | 6 | 2005 | 6065 | 0.120 |
Why?
|
Social Perception | 1 | 2014 | 76 | 0.120 |
Why?
|
Respiratory Rate | 1 | 2013 | 11 | 0.120 |
Why?
|
Carrier Proteins | 1 | 2002 | 2023 | 0.120 |
Why?
|
Protein Transport | 2 | 2018 | 735 | 0.120 |
Why?
|
Placebo Effect | 1 | 2013 | 39 | 0.120 |
Why?
|
Pulmonary Emphysema | 2 | 2006 | 145 | 0.110 |
Why?
|
Drug Therapy | 1 | 2014 | 206 | 0.110 |
Why?
|
Pain, Intractable | 2 | 2012 | 171 | 0.110 |
Why?
|
Injections, Spinal | 2 | 2012 | 257 | 0.110 |
Why?
|
Mycophenolic Acid | 1 | 2014 | 149 | 0.110 |
Why?
|
Infant, Newborn | 2 | 2017 | 8221 | 0.110 |
Why?
|
Rest | 1 | 2013 | 70 | 0.110 |
Why?
|
Genital Neoplasms, Female | 1 | 2020 | 741 | 0.110 |
Why?
|
Body Image | 1 | 2014 | 141 | 0.110 |
Why?
|
Indans | 1 | 2013 | 69 | 0.110 |
Why?
|
Vitamin D | 2 | 2014 | 261 | 0.110 |
Why?
|
Phenotype | 2 | 2022 | 6273 | 0.110 |
Why?
|
Acetaminophen | 1 | 2014 | 116 | 0.110 |
Why?
|
Perception | 1 | 2015 | 353 | 0.110 |
Why?
|
Sex Characteristics | 1 | 2015 | 416 | 0.110 |
Why?
|
Hypersensitivity, Immediate | 1 | 2012 | 25 | 0.110 |
Why?
|
Inflammation | 4 | 2021 | 2515 | 0.110 |
Why?
|
Radiography | 3 | 2014 | 1912 | 0.110 |
Why?
|
Evidence-Based Medicine | 1 | 2018 | 1098 | 0.110 |
Why?
|
Melatonin | 1 | 2013 | 46 | 0.110 |
Why?
|
Alcohol Drinking | 2 | 2015 | 553 | 0.110 |
Why?
|
Combined Modality Therapy | 2 | 2015 | 8883 | 0.110 |
Why?
|
Suicidal Ideation | 1 | 2015 | 207 | 0.110 |
Why?
|
Cross-Cultural Comparison | 2 | 2024 | 87 | 0.110 |
Why?
|
Review Literature as Topic | 1 | 2013 | 76 | 0.110 |
Why?
|
Analgesics, Non-Narcotic | 1 | 2014 | 127 | 0.110 |
Why?
|
Marriage | 1 | 2012 | 45 | 0.110 |
Why?
|
Analysis of Variance | 3 | 2018 | 2311 | 0.110 |
Why?
|
Respiratory Syncytial Virus, Human | 1 | 2015 | 211 | 0.110 |
Why?
|
APACHE | 1 | 2012 | 93 | 0.110 |
Why?
|
Dehydration | 1 | 2012 | 87 | 0.110 |
Why?
|
Genes, Viral | 1 | 2012 | 200 | 0.110 |
Why?
|
Quinolones | 1 | 2013 | 159 | 0.110 |
Why?
|
Skin Tests | 1 | 2012 | 96 | 0.110 |
Why?
|
Patient-Centered Care | 1 | 2015 | 298 | 0.110 |
Why?
|
Sulfur Dioxide | 1 | 2012 | 4 | 0.110 |
Why?
|
Japan | 2 | 2023 | 227 | 0.110 |
Why?
|
Music | 1 | 2012 | 36 | 0.110 |
Why?
|
Ascites | 1 | 2013 | 198 | 0.100 |
Why?
|
Nitrogen Dioxide | 1 | 2012 | 17 | 0.100 |
Why?
|
Immunoglobulin E | 1 | 2012 | 163 | 0.100 |
Why?
|
Toll-Like Receptors | 1 | 2013 | 173 | 0.100 |
Why?
|
Nursing Homes | 1 | 2012 | 99 | 0.100 |
Why?
|
Poisson Distribution | 1 | 2012 | 92 | 0.100 |
Why?
|
Personnel Staffing and Scheduling | 1 | 2012 | 90 | 0.100 |
Why?
|
Chi-Square Distribution | 3 | 2013 | 1329 | 0.100 |
Why?
|
Program Evaluation | 1 | 2014 | 602 | 0.100 |
Why?
|
Ozone | 1 | 2012 | 33 | 0.100 |
Why?
|
Medical Staff, Hospital | 1 | 2012 | 120 | 0.100 |
Why?
|
Sleep Deprivation | 1 | 2012 | 51 | 0.100 |
Why?
|
Body Height | 1 | 2012 | 231 | 0.100 |
Why?
|
Diabetes Mellitus | 1 | 2020 | 1066 | 0.100 |
Why?
|
Particle Size | 1 | 2012 | 186 | 0.100 |
Why?
|
Biomedical Research | 1 | 2019 | 807 | 0.100 |
Why?
|
Public Health | 1 | 2014 | 302 | 0.100 |
Why?
|
Saposins | 1 | 2011 | 1 | 0.100 |
Why?
|
Fibroblasts | 1 | 2018 | 1653 | 0.100 |
Why?
|
Phosphatidylcholine-Sterol O-Acyltransferase | 1 | 2011 | 5 | 0.100 |
Why?
|
Combinatorial Chemistry Techniques | 2 | 2002 | 37 | 0.100 |
Why?
|
Cathepsin D | 1 | 2011 | 32 | 0.100 |
Why?
|
Adult Survivors of Child Abuse | 1 | 2011 | 17 | 0.100 |
Why?
|
Constipation | 1 | 2012 | 177 | 0.100 |
Why?
|
Parenteral Nutrition | 1 | 2012 | 207 | 0.100 |
Why?
|
Particulate Matter | 1 | 2012 | 88 | 0.100 |
Why?
|
Emotions | 1 | 2015 | 567 | 0.100 |
Why?
|
World Health Organization | 2 | 2024 | 317 | 0.100 |
Why?
|
Critical Illness | 2 | 2014 | 714 | 0.100 |
Why?
|
Decision Support Techniques | 1 | 2016 | 623 | 0.100 |
Why?
|
Child Abuse, Sexual | 1 | 2011 | 35 | 0.100 |
Why?
|
Psychiatric Status Rating Scales | 2 | 2014 | 899 | 0.090 |
Why?
|
Gram-Negative Bacteria | 1 | 2011 | 100 | 0.090 |
Why?
|
Lipase | 1 | 2011 | 113 | 0.090 |
Why?
|
Disasters | 1 | 2012 | 107 | 0.090 |
Why?
|
Percutaneous Coronary Intervention | 1 | 2015 | 346 | 0.090 |
Why?
|
Reference Values | 1 | 2012 | 1098 | 0.090 |
Why?
|
Hospitals, Public | 1 | 2010 | 64 | 0.090 |
Why?
|
Catheters | 1 | 2011 | 129 | 0.090 |
Why?
|
Vitamin D Deficiency | 1 | 2011 | 116 | 0.090 |
Why?
|
Abdominal Pain | 1 | 2013 | 368 | 0.090 |
Why?
|
Activities of Daily Living | 3 | 2023 | 560 | 0.090 |
Why?
|
Respiratory Muscles | 1 | 2010 | 27 | 0.090 |
Why?
|
Muscle, Skeletal | 3 | 2012 | 1275 | 0.090 |
Why?
|
Gastrointestinal Diseases | 1 | 2015 | 587 | 0.090 |
Why?
|
Recovery of Function | 2 | 2023 | 718 | 0.090 |
Why?
|
Chemoradiotherapy, Adjuvant | 1 | 2013 | 565 | 0.090 |
Why?
|
Quality Control | 1 | 2011 | 459 | 0.090 |
Why?
|
Biomarkers, Tumor | 2 | 2008 | 10356 | 0.090 |
Why?
|
Depressive Disorder | 1 | 2014 | 557 | 0.090 |
Why?
|
Quarantine | 1 | 2009 | 20 | 0.090 |
Why?
|
Gastrectomy | 1 | 2013 | 451 | 0.090 |
Why?
|
Network Meta-Analysis | 2 | 2022 | 35 | 0.090 |
Why?
|
Healthcare Disparities | 1 | 2015 | 601 | 0.090 |
Why?
|
Leukemia | 1 | 2018 | 1632 | 0.090 |
Why?
|
Aminopyridines | 1 | 2011 | 212 | 0.090 |
Why?
|
Anaerobic Threshold | 1 | 2009 | 11 | 0.090 |
Why?
|
Genetic Variation | 1 | 2018 | 2087 | 0.090 |
Why?
|
Mice, Knockout | 4 | 2015 | 5680 | 0.090 |
Why?
|
Patient Care Management | 1 | 2010 | 94 | 0.090 |
Why?
|
Adipose Tissue | 2 | 2012 | 766 | 0.090 |
Why?
|
Muscle Strength | 1 | 2010 | 106 | 0.090 |
Why?
|
Analgesia | 1 | 2010 | 94 | 0.090 |
Why?
|
Status Asthmaticus | 1 | 2009 | 21 | 0.090 |
Why?
|
Air | 1 | 2009 | 63 | 0.090 |
Why?
|
Affective Symptoms | 1 | 2010 | 100 | 0.090 |
Why?
|
Garcinia | 1 | 2008 | 1 | 0.080 |
Why?
|
Fasting | 1 | 2011 | 350 | 0.080 |
Why?
|
Biflavonoids | 1 | 2008 | 4 | 0.080 |
Why?
|
Histone Deacetylases | 1 | 2011 | 364 | 0.080 |
Why?
|
Academic Medical Centers | 1 | 2012 | 673 | 0.080 |
Why?
|
Placebos | 1 | 2010 | 441 | 0.080 |
Why?
|
Mental Recall | 1 | 2010 | 172 | 0.080 |
Why?
|
Trachea | 1 | 2011 | 259 | 0.080 |
Why?
|
Long QT Syndrome | 1 | 2010 | 91 | 0.080 |
Why?
|
Tissue Distribution | 1 | 2010 | 878 | 0.080 |
Why?
|
Administration, Cutaneous | 1 | 2009 | 143 | 0.080 |
Why?
|
Health Care Surveys | 1 | 2010 | 429 | 0.080 |
Why?
|
Antifungal Agents | 1 | 2014 | 840 | 0.080 |
Why?
|
Health Surveys | 1 | 2010 | 410 | 0.080 |
Why?
|
British Columbia | 1 | 2008 | 24 | 0.080 |
Why?
|
Travel | 1 | 2009 | 198 | 0.080 |
Why?
|
Tunica Intima | 1 | 2008 | 116 | 0.080 |
Why?
|
Life Expectancy | 1 | 2008 | 133 | 0.080 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2010 | 15874 | 0.080 |
Why?
|
Head and Neck Neoplasms | 2 | 2014 | 3978 | 0.080 |
Why?
|
Peptide Fragments | 2 | 2005 | 1265 | 0.080 |
Why?
|
Neopterin | 1 | 2007 | 13 | 0.080 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2010 | 867 | 0.080 |
Why?
|
Drug Evaluation | 1 | 2008 | 425 | 0.080 |
Why?
|
Prednisone | 1 | 2010 | 983 | 0.080 |
Why?
|
Carcinoembryonic Antigen | 1 | 2008 | 223 | 0.080 |
Why?
|
Medication Adherence | 1 | 2012 | 499 | 0.080 |
Why?
|
Alemtuzumab | 1 | 2008 | 196 | 0.080 |
Why?
|
Membrane Proteins | 2 | 2017 | 2817 | 0.080 |
Why?
|
Anti-Asthmatic Agents | 1 | 2009 | 118 | 0.080 |
Why?
|
Atherosclerosis | 1 | 2015 | 937 | 0.070 |
Why?
|
Myocytes, Smooth Muscle | 1 | 2008 | 199 | 0.070 |
Why?
|
Viral Vaccines | 1 | 2009 | 304 | 0.070 |
Why?
|
Snoring | 1 | 2006 | 13 | 0.070 |
Why?
|
Gene Rearrangement, B-Lymphocyte | 1 | 2006 | 47 | 0.070 |
Why?
|
Genes, Immunoglobulin Heavy Chain | 1 | 2006 | 38 | 0.070 |
Why?
|
Muscle, Smooth, Vascular | 1 | 2008 | 329 | 0.070 |
Why?
|
Calcitonin | 1 | 2007 | 186 | 0.070 |
Why?
|
Chemoradiotherapy | 2 | 2013 | 1947 | 0.070 |
Why?
|
Somatic Hypermutation, Immunoglobulin | 1 | 2006 | 47 | 0.070 |
Why?
|
Immunologic Factors | 1 | 2010 | 653 | 0.070 |
Why?
|
United Kingdom | 2 | 2022 | 259 | 0.070 |
Why?
|
Diagnosis, Differential | 2 | 2014 | 4756 | 0.070 |
Why?
|
Nurses | 2 | 2019 | 82 | 0.070 |
Why?
|
Vincristine | 1 | 2010 | 1511 | 0.070 |
Why?
|
Psychotherapy, Group | 1 | 2006 | 58 | 0.070 |
Why?
|
Occupational Health | 1 | 2006 | 95 | 0.070 |
Why?
|
Accidents, Traffic | 1 | 2006 | 117 | 0.070 |
Why?
|
Benzamides | 1 | 2011 | 1834 | 0.070 |
Why?
|
Protein Precursors | 1 | 2007 | 240 | 0.070 |
Why?
|
Immunoglobulin Variable Region | 1 | 2006 | 173 | 0.070 |
Why?
|
Neutropenia | 2 | 2008 | 968 | 0.070 |
Why?
|
Chemokine CXCL1 | 1 | 2005 | 61 | 0.070 |
Why?
|
Equipment Failure | 1 | 2006 | 191 | 0.070 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 1489 | 0.070 |
Why?
|
Copper Sulfate | 1 | 2005 | 4 | 0.070 |
Why?
|
Apolipoprotein E3 | 1 | 2005 | 16 | 0.070 |
Why?
|
Immunocompromised Host | 1 | 2010 | 697 | 0.070 |
Why?
|
Equipment Design | 1 | 2009 | 1207 | 0.070 |
Why?
|
Respiratory Sounds | 1 | 2006 | 95 | 0.070 |
Why?
|
Neuropsychological Tests | 1 | 2010 | 1174 | 0.070 |
Why?
|
Rituximab | 1 | 2010 | 1535 | 0.060 |
Why?
|
Tubulin | 1 | 2005 | 169 | 0.060 |
Why?
|
Lymphoproliferative Disorders | 1 | 2008 | 367 | 0.060 |
Why?
|
Residence Characteristics | 1 | 2008 | 349 | 0.060 |
Why?
|
Thrombocytopenia | 2 | 2008 | 847 | 0.060 |
Why?
|
Lipoproteins, LDL | 1 | 2005 | 164 | 0.060 |
Why?
|
Lipid Peroxidation | 1 | 2005 | 156 | 0.060 |
Why?
|
Tomography, X-Ray Computed | 4 | 2004 | 7573 | 0.060 |
Why?
|
Mycosis Fungoides | 1 | 2008 | 320 | 0.060 |
Why?
|
Task Performance and Analysis | 1 | 2005 | 137 | 0.060 |
Why?
|
Population Surveillance | 1 | 2008 | 628 | 0.060 |
Why?
|
Occupational Diseases | 1 | 2005 | 132 | 0.060 |
Why?
|
Personnel, Hospital | 1 | 2004 | 40 | 0.060 |
Why?
|
Postoperative Complications | 1 | 2019 | 5565 | 0.060 |
Why?
|
Ki-67 Antigen | 1 | 2005 | 669 | 0.060 |
Why?
|
Oxycodone | 1 | 2023 | 29 | 0.060 |
Why?
|
Taiwan | 1 | 2023 | 93 | 0.060 |
Why?
|
Extracorporeal Membrane Oxygenation | 1 | 2009 | 586 | 0.060 |
Why?
|
Repressor Proteins | 1 | 2011 | 1663 | 0.060 |
Why?
|
Cyclophosphamide | 1 | 2010 | 3002 | 0.060 |
Why?
|
Doxorubicin | 1 | 2010 | 3005 | 0.060 |
Why?
|
Hydroxylamines | 1 | 2022 | 8 | 0.060 |
Why?
|
Levorphanol | 1 | 2023 | 14 | 0.060 |
Why?
|
Lysine | 1 | 2005 | 423 | 0.060 |
Why?
|
Morphine Derivatives | 1 | 2022 | 9 | 0.050 |
Why?
|
Chromosomal Proteins, Non-Histone | 1 | 2005 | 362 | 0.050 |
Why?
|
Thyrotropin | 2 | 2014 | 117 | 0.050 |
Why?
|
Protein Isoforms | 1 | 2005 | 835 | 0.050 |
Why?
|
Medical Records | 2 | 2015 | 414 | 0.050 |
Why?
|
Neoplasm Metastasis | 1 | 2013 | 5121 | 0.050 |
Why?
|
Microfilament Proteins | 1 | 2005 | 488 | 0.050 |
Why?
|
Amino Acid Motifs | 2 | 2000 | 394 | 0.050 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2012 | 10066 | 0.050 |
Why?
|
Patient Acceptance of Health Care | 2 | 2010 | 587 | 0.050 |
Why?
|
Pneumococcal Infections | 1 | 2004 | 242 | 0.050 |
Why?
|
Pleural Effusion | 1 | 2004 | 201 | 0.050 |
Why?
|
Interviews as Topic | 2 | 2015 | 500 | 0.050 |
Why?
|
Oncogenes | 1 | 2005 | 672 | 0.050 |
Why?
|
Germany | 1 | 2022 | 112 | 0.050 |
Why?
|
Multicenter Studies as Topic | 1 | 2023 | 544 | 0.050 |
Why?
|
Hospitals, University | 1 | 2002 | 211 | 0.050 |
Why?
|
Hemolysis | 1 | 2002 | 126 | 0.050 |
Why?
|
Arginine | 1 | 2005 | 500 | 0.050 |
Why?
|
Hematologic Diseases | 1 | 2003 | 242 | 0.050 |
Why?
|
Hemoglobins | 3 | 2014 | 477 | 0.050 |
Why?
|
Administration, Oral | 2 | 2018 | 1556 | 0.050 |
Why?
|
Protein Structure, Tertiary | 1 | 2005 | 1489 | 0.050 |
Why?
|
Metoclopramide | 1 | 2021 | 33 | 0.050 |
Why?
|
Drug Administration Schedule | 2 | 2020 | 3478 | 0.050 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2021 | 6915 | 0.050 |
Why?
|
RNA, Ribosomal, 16S | 1 | 2023 | 485 | 0.050 |
Why?
|
Transferases | 1 | 2021 | 9 | 0.050 |
Why?
|
Gene Library | 1 | 2002 | 293 | 0.050 |
Why?
|
Mediastinal Neoplasms | 1 | 2005 | 423 | 0.050 |
Why?
|
Hepatitis B Surface Antigens | 1 | 2021 | 84 | 0.050 |
Why?
|
Nose | 1 | 2023 | 192 | 0.050 |
Why?
|
Triazines | 1 | 2022 | 117 | 0.050 |
Why?
|
Tertiary Healthcare | 1 | 2021 | 45 | 0.050 |
Why?
|
Herpesvirus 3, Human | 1 | 2021 | 44 | 0.050 |
Why?
|
Mutagenesis, Site-Directed | 1 | 2002 | 606 | 0.050 |
Why?
|
Bronchoscopy | 1 | 2004 | 474 | 0.050 |
Why?
|
Harm Reduction | 1 | 2020 | 16 | 0.050 |
Why?
|
Fever | 2 | 2020 | 497 | 0.050 |
Why?
|
Protein Binding | 2 | 2005 | 3443 | 0.050 |
Why?
|
Lopinavir | 1 | 2020 | 12 | 0.050 |
Why?
|
Vero Cells | 1 | 2021 | 144 | 0.050 |
Why?
|
Pleural Neoplasms | 1 | 2005 | 470 | 0.050 |
Why?
|
Biological Transport | 1 | 2002 | 597 | 0.050 |
Why?
|
Medical History Taking | 1 | 2021 | 176 | 0.050 |
Why?
|
Authoritarianism | 1 | 2020 | 10 | 0.050 |
Why?
|
Malaysia | 1 | 2020 | 20 | 0.050 |
Why?
|
Cognition | 1 | 2006 | 975 | 0.050 |
Why?
|
Neutralization Tests | 1 | 2021 | 298 | 0.050 |
Why?
|
Cell Differentiation | 1 | 2011 | 4052 | 0.050 |
Why?
|
Liver Function Tests | 1 | 2020 | 173 | 0.050 |
Why?
|
Morpholines | 1 | 2022 | 289 | 0.050 |
Why?
|
Hope | 1 | 2020 | 13 | 0.050 |
Why?
|
Cell Cycle | 2 | 2021 | 2087 | 0.050 |
Why?
|
Hospital Units | 2 | 2010 | 38 | 0.050 |
Why?
|
Mesothelioma | 1 | 2005 | 544 | 0.040 |
Why?
|
Cultural Characteristics | 1 | 2019 | 70 | 0.040 |
Why?
|
Humidity | 1 | 2019 | 29 | 0.040 |
Why?
|
Anti-Infective Agents | 2 | 2014 | 446 | 0.040 |
Why?
|
Antibody Formation | 1 | 2020 | 383 | 0.040 |
Why?
|
Recombinant Proteins | 1 | 2005 | 2917 | 0.040 |
Why?
|
Gastrostomy | 1 | 2021 | 180 | 0.040 |
Why?
|
Hepatitis B virus | 1 | 2021 | 215 | 0.040 |
Why?
|
Pyridones | 1 | 2022 | 349 | 0.040 |
Why?
|
Oligodeoxyribonucleotides | 1 | 2000 | 257 | 0.040 |
Why?
|
Mice | 5 | 2015 | 34442 | 0.040 |
Why?
|
Observational Studies as Topic | 1 | 2019 | 144 | 0.040 |
Why?
|
Immunization, Passive | 1 | 2020 | 171 | 0.040 |
Why?
|
Adjuvants, Immunologic | 1 | 2023 | 660 | 0.040 |
Why?
|
Oligopeptides | 1 | 2021 | 430 | 0.040 |
Why?
|
Base Sequence | 3 | 2000 | 4890 | 0.040 |
Why?
|
Sequence Deletion | 1 | 2002 | 875 | 0.040 |
Why?
|
Airway Management | 1 | 2020 | 102 | 0.040 |
Why?
|
Pneumonectomy | 1 | 2004 | 832 | 0.040 |
Why?
|
DNA, Bacterial | 1 | 2021 | 557 | 0.040 |
Why?
|
Specimen Handling | 1 | 2020 | 299 | 0.040 |
Why?
|
Counseling | 1 | 2021 | 382 | 0.040 |
Why?
|
Algorithms | 1 | 2010 | 3891 | 0.040 |
Why?
|
L-Lactate Dehydrogenase | 3 | 2004 | 300 | 0.040 |
Why?
|
Apolipoprotein A-I | 1 | 2018 | 84 | 0.040 |
Why?
|
Peritoneal Neoplasms | 1 | 2005 | 828 | 0.040 |
Why?
|
Bacteremia | 1 | 2004 | 689 | 0.040 |
Why?
|
Adenosine Triphosphate | 1 | 2000 | 573 | 0.040 |
Why?
|
Curriculum | 1 | 2023 | 863 | 0.040 |
Why?
|
Temperature | 1 | 2019 | 508 | 0.040 |
Why?
|
Cholesterol | 1 | 2021 | 657 | 0.040 |
Why?
|
Stents | 1 | 2004 | 1099 | 0.040 |
Why?
|
Immunohistochemistry | 2 | 2005 | 7558 | 0.040 |
Why?
|
Behavior, Addictive | 1 | 2018 | 98 | 0.040 |
Why?
|
Cluster Analysis | 1 | 2020 | 1055 | 0.040 |
Why?
|
Respiration, Artificial | 2 | 2015 | 578 | 0.040 |
Why?
|
Appetite Stimulants | 1 | 2017 | 14 | 0.040 |
Why?
|
Protein Stability | 1 | 2018 | 371 | 0.040 |
Why?
|
Electrocardiography | 2 | 2015 | 1145 | 0.040 |
Why?
|
Anxiety Disorders | 1 | 2023 | 678 | 0.040 |
Why?
|
Genotyping Techniques | 1 | 2017 | 166 | 0.040 |
Why?
|
Cyclohexanecarboxylic Acids | 1 | 2016 | 42 | 0.040 |
Why?
|
Clonidine | 1 | 2016 | 71 | 0.040 |
Why?
|
Protein Conformation | 1 | 2000 | 1259 | 0.040 |
Why?
|
Salmeterol Xinafoate | 1 | 2016 | 22 | 0.040 |
Why?
|
Antibodies, Monoclonal, Humanized | 1 | 2008 | 3262 | 0.040 |
Why?
|
Safety-net Providers | 1 | 2016 | 53 | 0.040 |
Why?
|
Fluticasone | 1 | 2016 | 23 | 0.040 |
Why?
|
Amines | 1 | 2016 | 85 | 0.040 |
Why?
|
Chronic Pain | 1 | 2020 | 247 | 0.040 |
Why?
|
Infusions, Intravenous | 1 | 2019 | 1381 | 0.030 |
Why?
|
Hypoxia | 1 | 2019 | 445 | 0.030 |
Why?
|
RNA | 1 | 2021 | 1011 | 0.030 |
Why?
|
Marital Status | 1 | 2015 | 96 | 0.030 |
Why?
|
Breast Neoplasms | 1 | 2020 | 15710 | 0.030 |
Why?
|
Triglycerides | 1 | 2018 | 604 | 0.030 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2008 | 2392 | 0.030 |
Why?
|
Phylogeny | 2 | 2012 | 826 | 0.030 |
Why?
|
gamma-Aminobutyric Acid | 1 | 2016 | 269 | 0.030 |
Why?
|
Drug Administration Routes | 1 | 2014 | 62 | 0.030 |
Why?
|
Autophagy | 1 | 2021 | 930 | 0.030 |
Why?
|
Prostatic Neoplasms | 1 | 2011 | 5777 | 0.030 |
Why?
|
Phagocytosis | 1 | 2015 | 256 | 0.030 |
Why?
|
PPAR gamma | 1 | 2015 | 230 | 0.030 |
Why?
|
Gene Frequency | 1 | 2017 | 1164 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 2 | 2018 | 5541 | 0.030 |
Why?
|
Energy Intake | 1 | 2017 | 518 | 0.030 |
Why?
|
Vitamin B 12 | 1 | 2014 | 73 | 0.030 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 1998 | 857 | 0.030 |
Why?
|
Educational Status | 1 | 2015 | 396 | 0.030 |
Why?
|
Tiotropium Bromide | 1 | 2013 | 23 | 0.030 |
Why?
|
Scopolamine Derivatives | 1 | 2013 | 15 | 0.030 |
Why?
|
HEK293 Cells | 1 | 2018 | 1505 | 0.030 |
Why?
|
Pneumonia, Staphylococcal | 1 | 2013 | 16 | 0.030 |
Why?
|
Personal Satisfaction | 1 | 2014 | 140 | 0.030 |
Why?
|
Hydrocodone | 1 | 2014 | 55 | 0.030 |
Why?
|
Mitochondria | 1 | 2000 | 1284 | 0.030 |
Why?
|
Early Detection of Cancer | 1 | 2021 | 1266 | 0.030 |
Why?
|
Observer Variation | 1 | 2014 | 672 | 0.030 |
Why?
|
Alcohol Withdrawal Seizures | 1 | 2012 | 4 | 0.030 |
Why?
|
Developing Countries | 1 | 2015 | 315 | 0.030 |
Why?
|
Self Concept | 1 | 2014 | 212 | 0.030 |
Why?
|
DNA | 1 | 2021 | 2681 | 0.030 |
Why?
|
Mice, Inbred C57BL | 2 | 2015 | 6916 | 0.030 |
Why?
|
Colorectal Neoplasms | 1 | 2008 | 3583 | 0.030 |
Why?
|
Diagnostic Self Evaluation | 1 | 2012 | 33 | 0.030 |
Why?
|
Causality | 1 | 2012 | 178 | 0.030 |
Why?
|
Inhibitory Concentration 50 | 1 | 2012 | 291 | 0.030 |
Why?
|
Hemagglutinin Glycoproteins, Influenza Virus | 1 | 2012 | 73 | 0.030 |
Why?
|
Pyriform Sinus | 1 | 2011 | 8 | 0.030 |
Why?
|
Administration, Intravenous | 1 | 2012 | 249 | 0.030 |
Why?
|
Cell Line, Tumor | 2 | 2018 | 14594 | 0.020 |
Why?
|
3T3-L1 Cells | 1 | 2011 | 78 | 0.020 |
Why?
|
Cyclopropanes | 1 | 2011 | 88 | 0.020 |
Why?
|
Paclitaxel | 1 | 1998 | 1998 | 0.020 |
Why?
|
Anthropometry | 1 | 2012 | 269 | 0.020 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2003 | 2342 | 0.020 |
Why?
|
Pharyngeal Neoplasms | 1 | 2011 | 133 | 0.020 |
Why?
|
Medical Audit | 1 | 2011 | 189 | 0.020 |
Why?
|
Androgens | 1 | 2014 | 512 | 0.020 |
Why?
|
Maximum Tolerated Dose | 1 | 2014 | 1291 | 0.020 |
Why?
|
Hemagglutinins, Viral | 1 | 2010 | 45 | 0.020 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 1 | 2013 | 308 | 0.020 |
Why?
|
Drug Prescriptions | 1 | 2012 | 290 | 0.020 |
Why?
|
Immunoprecipitation | 1 | 2011 | 591 | 0.020 |
Why?
|
Data Collection | 1 | 2012 | 626 | 0.020 |
Why?
|
Microbial Sensitivity Tests | 1 | 2012 | 997 | 0.020 |
Why?
|
Hormone Replacement Therapy | 1 | 2011 | 205 | 0.020 |
Why?
|
Macrophages | 1 | 2015 | 1300 | 0.020 |
Why?
|
Viral Matrix Proteins | 1 | 2010 | 201 | 0.020 |
Why?
|
Pseudopodia | 1 | 2008 | 30 | 0.020 |
Why?
|
Self-Assessment | 1 | 2009 | 98 | 0.020 |
Why?
|
Alberta | 1 | 2008 | 65 | 0.020 |
Why?
|
Chemotaxis | 1 | 2008 | 139 | 0.020 |
Why?
|
Body Weight | 1 | 2013 | 1291 | 0.020 |
Why?
|
Methadone | 1 | 2010 | 195 | 0.020 |
Why?
|
Apoptosis | 2 | 2015 | 7608 | 0.020 |
Why?
|
Hyperplasia | 1 | 2008 | 558 | 0.020 |
Why?
|
Carotid Stenosis | 1 | 2008 | 176 | 0.020 |
Why?
|
RNA, Messenger | 2 | 2011 | 6132 | 0.020 |
Why?
|
Dendritic Cells | 1 | 2013 | 1085 | 0.020 |
Why?
|
Calcitonin Gene-Related Peptide | 1 | 2007 | 163 | 0.020 |
Why?
|
Health Care Costs | 1 | 2011 | 677 | 0.020 |
Why?
|
Sequence Homology, Nucleic Acid | 1 | 2006 | 349 | 0.020 |
Why?
|
Down-Regulation | 1 | 2011 | 2079 | 0.020 |
Why?
|
Chemokine CXCL10 | 1 | 2005 | 105 | 0.020 |
Why?
|
Asbestos | 1 | 2005 | 35 | 0.020 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2017 | 4554 | 0.020 |
Why?
|
Computer Simulation | 1 | 2010 | 1532 | 0.020 |
Why?
|
Pulmonary Diffusing Capacity | 1 | 2004 | 36 | 0.020 |
Why?
|
Convalescence | 1 | 2004 | 25 | 0.020 |
Why?
|
Sequence Analysis, DNA | 1 | 2012 | 2479 | 0.020 |
Why?
|
Pulmonary Gas Exchange | 1 | 2004 | 41 | 0.020 |
Why?
|
Fuzzy Logic | 1 | 2004 | 8 | 0.020 |
Why?
|
Carcinoma, Bronchogenic | 1 | 2004 | 34 | 0.020 |
Why?
|
Tuberculosis, Pleural | 1 | 2004 | 11 | 0.020 |
Why?
|
Chills | 1 | 2003 | 16 | 0.010 |
Why?
|
Recurrence | 1 | 2012 | 4764 | 0.010 |
Why?
|
Occupational Exposure | 1 | 2005 | 246 | 0.010 |
Why?
|
Rectal Neoplasms | 1 | 2011 | 1203 | 0.010 |
Why?
|
Autopsy | 1 | 2003 | 174 | 0.010 |
Why?
|
Contact Tracing | 1 | 2003 | 56 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2015 | 7249 | 0.010 |
Why?
|
Methylprednisolone | 1 | 2003 | 193 | 0.010 |
Why?
|
Platelet Count | 1 | 2003 | 490 | 0.010 |
Why?
|
Blood Coagulation | 1 | 2003 | 185 | 0.010 |
Why?
|
Pulmonary Fibrosis | 1 | 2003 | 170 | 0.010 |
Why?
|
Lymphocyte Count | 1 | 2003 | 487 | 0.010 |
Why?
|
Clinical Protocols | 1 | 2004 | 465 | 0.010 |
Why?
|
Minimally Invasive Surgical Procedures | 1 | 2004 | 502 | 0.010 |
Why?
|
Lymphopenia | 1 | 2003 | 199 | 0.010 |
Why?
|
Physical Chromosome Mapping | 1 | 2000 | 73 | 0.010 |
Why?
|
Rats | 2 | 2000 | 6109 | 0.010 |
Why?
|
DNA Mutational Analysis | 1 | 2006 | 2282 | 0.010 |
Why?
|
Intracellular Membranes | 1 | 2000 | 107 | 0.010 |
Why?
|
Pseudogenes | 1 | 2000 | 81 | 0.010 |
Why?
|
Registries | 1 | 2008 | 2187 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2008 | 5606 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2015 | 8894 | 0.010 |
Why?
|
Chromosomes, Human, Pair 15 | 1 | 2000 | 231 | 0.010 |
Why?
|
Chromosomes, Human, Pair 1 | 1 | 2000 | 328 | 0.010 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2000 | 995 | 0.010 |
Why?
|
Sequence Alignment | 1 | 2000 | 844 | 0.010 |
Why?
|
Genotype | 1 | 2006 | 4108 | 0.010 |
Why?
|
Cloning, Molecular | 1 | 2000 | 1207 | 0.010 |
Why?
|
Chromosomes, Human, Pair 2 | 1 | 1998 | 172 | 0.010 |
Why?
|
DNA Primers | 1 | 2000 | 1394 | 0.010 |
Why?
|
Drug Resistance | 1 | 1998 | 586 | 0.010 |
Why?
|
Radiotherapy Dosage | 1 | 2003 | 3847 | 0.010 |
Why?
|
Neoplasm Invasiveness | 1 | 2003 | 3987 | 0.010 |
Why?
|
Transfection | 1 | 2000 | 2935 | 0.010 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2011 | 5436 | 0.010 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2000 | 2233 | 0.010 |
Why?
|
Chromosome Mapping | 1 | 1998 | 1463 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2005 | 4028 | 0.010 |
Why?
|
Cell Line | 1 | 2000 | 5088 | 0.010 |
Why?
|
Bone Marrow | 1 | 2000 | 2360 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2000 | 5158 | 0.000 |
Why?
|
Mutation | 1 | 2006 | 15195 | 0.000 |
Why?
|